CN102803199B - 乙酰水杨酸盐 - Google Patents

乙酰水杨酸盐 Download PDF

Info

Publication number
CN102803199B
CN102803199B CN201080028833.9A CN201080028833A CN102803199B CN 102803199 B CN102803199 B CN 102803199B CN 201080028833 A CN201080028833 A CN 201080028833A CN 102803199 B CN102803199 B CN 102803199B
Authority
CN
China
Prior art keywords
masa
acetylsalicylic acid
asa
test
control group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080028833.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102803199A (zh
Inventor
爱华斯·凯文希
安那东利杰斯·柏门斯
马利斯·菲佛利斯
安多司·拉贝帝夫斯
安那东利杰斯·米斯诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tetra Sia
Original Assignee
Tetra Sia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from LVP-09-117A external-priority patent/LV14273B/lv
Application filed by Tetra Sia filed Critical Tetra Sia
Priority claimed from LVP-10-95A external-priority patent/LV14468B/lv
Publication of CN102803199A publication Critical patent/CN102803199A/zh
Application granted granted Critical
Publication of CN102803199B publication Critical patent/CN102803199B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/40—Hydrazines having nitrogen atoms of hydrazine groups being quaternised
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/14—Acetic acid esters of monohydroxylic compounds
    • C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
    • C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201080028833.9A 2009-06-25 2010-06-21 乙酰水杨酸盐 Expired - Fee Related CN102803199B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LVP-09-117A LV14273B (lv) 2009-06-25 2009-06-25 Jauni acetilsalicilskābes sāļi
LVP-09-117 2009-06-25
LVP-10-95 2010-06-21
PCT/LV2010/000007 WO2010151095A1 (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
LVP-10-95A LV14468B (lv) 2010-06-21 2010-06-21 Pretiekaisuma līdzeklis

Publications (2)

Publication Number Publication Date
CN102803199A CN102803199A (zh) 2012-11-28
CN102803199B true CN102803199B (zh) 2015-04-15

Family

ID=42562394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080028833.9A Expired - Fee Related CN102803199B (zh) 2009-06-25 2010-06-21 乙酰水杨酸盐

Country Status (12)

Country Link
US (1) US8889902B2 (enExample)
EP (1) EP2445861B1 (enExample)
JP (1) JP5706409B2 (enExample)
KR (1) KR20120050437A (enExample)
CN (1) CN102803199B (enExample)
BR (1) BRPI1009600A2 (enExample)
CA (1) CA2766048A1 (enExample)
EA (1) EA021588B1 (enExample)
GE (1) GEP20146015B (enExample)
IL (1) IL217036A (enExample)
NZ (1) NZ597510A (enExample)
WO (1) WO2010151095A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140088125A1 (en) * 2011-04-27 2014-03-27 Jsc Grindeks Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
CN103547562A (zh) * 2011-04-27 2014-01-29 格林代克斯联合股份公司 4-[(卤代烷基)(二甲基)铵基]丁酸盐及其在治疗心血管疾病中的用途
LV14606B (lv) 2011-05-17 2013-01-20 Tetra, Sia Jauns XII faktora inhibitors
RU2458054C1 (ru) * 2011-05-31 2012-08-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний) пропионата - никотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью
RU2457202C1 (ru) * 2011-05-31 2012-07-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - 5- гидрокисиникотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью
RU2465268C1 (ru) * 2011-08-08 2012-10-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Производное 3-(2,2,2-триметилгидразиний)пропионата - никотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai
JO3117B1 (ar) * 2012-12-20 2017-09-20 Grindeks Jsc استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين
LV14963B (lv) 2013-06-28 2015-10-20 Tetra, Sia Endoteliālās disfunkcijas korektors
GB201413355D0 (en) * 2014-07-28 2014-09-10 Innospec Ltd Compositons and methods
CN104997754A (zh) * 2015-08-05 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种解热镇痛药阿司匹林组合物胶囊
CN105106134A (zh) * 2015-09-23 2015-12-02 青岛华之草医药科技有限公司 一种解热镇痛抗炎药阿司匹林组合物颗粒剂
CN106008257A (zh) * 2016-03-16 2016-10-12 江苏悦兴药业有限公司 米屈肼的制备方法及其关键中间体
WO2018222583A1 (en) 2017-05-30 2018-12-06 Rho Pharmaceuticals, Llc In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin)
RU2694835C1 (ru) * 2018-12-07 2019-07-17 Федеральное государственное автономное образовательное учреждение высшего образования "Северный (Арктический) федеральный университет имени М.В. Ломоносова" Средство, повышающее резистентность организма в постгипотермическом периоде
JP2024511323A (ja) * 2021-03-08 2024-03-13 エルジー ハウスホールド アンド ヘルスケア リミテッド カルニチンサリシレートを有効成分として含む化粧料組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227513A (en) * 1990-07-04 1993-07-13 Lonza Ltd. Acetylsalicyloyl-L-carnitine and process for its production
CN101248036A (zh) * 2005-06-02 2008-08-20 拜耳医药保健股份公司 邻乙酰基水杨酸与碱性氨基酸的盐和甘氨酸的稳定的活性物质络合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3312593A (en) 1965-03-10 1967-04-04 Carter Prod Inc Anti-inflammatory compositions of aspirin and niacin
JPS5610110A (en) * 1979-07-06 1981-02-02 Green Cross Corp:The Acetyl salicylate salt preparation for injection
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US4625888A (en) 1985-11-18 1986-12-02 Thompson Andy L Ground actuated lid operating system
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
WO1996032942A1 (en) 1995-04-19 1996-10-24 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FR2751540B1 (fr) 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US6469035B1 (en) 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
DE19839443A1 (de) * 1998-08-29 2000-03-02 Miklos Ghyczy Arnzneimittel mit entzündungshemmender Wirkung
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
DE10202019A1 (de) * 2002-01-18 2003-07-24 Bayer Ag Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II
DK1667960T3 (da) * 2003-08-04 2008-06-09 Grindeks Jsc Meldoniumsalte, fremgangsmåde til deres fremstilling og farmaceutisk sammensætning på deres basis
JP2008533044A (ja) 2005-03-11 2008-08-21 ホン コン ナイトリック オキサイド リミテッド 内皮機能不全、アンギナおよび糖尿病のための組合せ治療
LV13544B (en) * 2005-08-15 2007-05-20 Grindeks As Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
ITMI20052459A1 (it) * 2005-12-22 2007-06-23 Isagro Spa Sali quaternari e relativo uso per il controllo di fitopatogeni
RU2010151944A (ru) 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227513A (en) * 1990-07-04 1993-07-13 Lonza Ltd. Acetylsalicyloyl-L-carnitine and process for its production
CN101248036A (zh) * 2005-06-02 2008-08-20 拜耳医药保健股份公司 邻乙酰基水杨酸与碱性氨基酸的盐和甘氨酸的稳定的活性物质络合物

Also Published As

Publication number Publication date
WO2010151095A8 (en) 2012-05-18
EA201200038A1 (ru) 2012-10-30
US20120088742A1 (en) 2012-04-12
JP5706409B2 (ja) 2015-04-22
HK1169648A1 (en) 2013-02-01
IL217036A (en) 2015-03-31
EP2445861B1 (en) 2014-03-26
WO2010151095A1 (en) 2010-12-29
EA021588B1 (ru) 2015-07-30
US8889902B2 (en) 2014-11-18
CA2766048A1 (en) 2010-12-29
JP2012531408A (ja) 2012-12-10
IL217036A0 (en) 2012-02-29
GEP20146015B (en) 2014-01-27
NZ597510A (en) 2012-12-21
KR20120050437A (ko) 2012-05-18
CN102803199A (zh) 2012-11-28
BRPI1009600A2 (enExample) 2016-03-22
EP2445861A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
CN102803199B (zh) 乙酰水杨酸盐
KR100674122B1 (ko) 관절증 치료용 파네실 단백질 트랜스퍼라제 억제제
US12280029B2 (en) Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
WO2010151096A1 (en) Therapeutic combinations of nicotinic acid and meldonium
Wallace et al. Nitric oxide-releasing NSAIDs: GI-safe antithrombotics
US11400066B2 (en) Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
TWI478715B (zh) 新穎乙醯柳酸鹽
AU2010263409B2 (en) Novel acetylsalicylic acid salts
WO2020058917A1 (en) Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
JP2022501315A (ja) 病的炎症の新しい医療
HK1169648B (en) Novel acetylsalicylic acid salts
WO2012158003A1 (en) Novel factor xii inhibitor
LV14468B (lv) Pretiekaisuma līdzeklis
TWI487524B (zh) 菸鹼酸和米曲肼之新穎治療組合
JPH07118156A (ja) アデノシンデアミナーゼ阻害剤
WO2011115527A1 (ru) Новое биологически активное соединение n-[3-(4-нитрофениламино)- индол-2-илметилен]аминогуанидина гидрохлорид с противовоспалительной активностью
ES2370134T3 (es) Empleo médico del hidrógeno fumarato y del dihidrógeno fosfato del propionato de 3-(2,2,2-trimetilhidrazinio).
WO2014209092A1 (en) Corrector of endothelial dysfunction
LV14462B (lv) Kombinēts medicīnisks produkts trombocītu salipšanas kavēšanai
CN1546044A (zh) 乙酰水杨酸的金属化合物的用途方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150415

Termination date: 20160621

CF01 Termination of patent right due to non-payment of annual fee